Download pdf
Progress in autoimmune disease and vaccine
- 1 School of Biomedical Science and Engineering, South China University of Technology, Guangzhou, China
* Author to whom correspondence should be addressed.
Abstract
Autoimmune diseases (ADs) are caused by an overactive immune system, which frequently results in irreversible damage to organs and physiological systems. Despite the extensive research conducted on Autoimmune Diseases (ADs) over numerous years, the etiology and contributory factors remain only partially elucidated. Presently, the therapeutic drugs encompasses glucocorticoids (GCs), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). However, these agents exert a modicum of efficacy against the malady, and are prone to elicit severe adverse reactions as well as drug resistance. Therefore, the development of vaccines targeting the pathogenesis of ADs may bring great progress to the treatment of ADs. This article delineates the concepts underpinning vaccine development leveraging human immune tolerance, encompassing the induction of tolerance, the targeting of pathogenic T cells, and the engagement of regulatory pathways. Concurrently, the paper expounds upon certain vaccine technologies that have emerged in the study of specific autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and multiple sclerosis.
Keywords
ADs, vaccine, immune tolerance
[1]. Guan, S. Y., Leng, R. X., Khan, M. I., Qureshi, H., Li, X. P., Ye, D. Q., & Pan, H. F. (2017). Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases. Inflammation, 40(1), 303–310. https://doi.org/10.1007/s10753-016-0453-9.
[2]. Theofilopoulos, A. N., Kono, D. H., & Baccala, R. (2017). The multiple pathways to autoimmunity. Nature immunology, 18(7), 716–724. https://doi.org/10.1038/ni.3731.
[3]. Conrad, N., Misra, S., Verbakel, J. Y., Verbeke, G., Molenberghs, G., Taylor, P. N., Mason, J., Sattar, N., McMurray, J. J. V., McInnes, I. B., Khunti, K., & Cambridge, G. (2023). Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet (London, England), 401(10391), 1878–1890. https://doi.org/10.1016/S0140-6736(23)00457-9
[4]. Horwitz, D. A., Fahmy, T. M., Piccirillo, C. A., & La Cava, A. (2019). Rebalancing Immune Homeostasis to Treat Autoimmune Diseases. Trends in immunology, 40(10), 888–908. https://doi.org/10.1016/j.it.2019.08.003
[5]. Dolgin E. (2024). Why autoimmune disease is more common in women: X chromosome holds clues. Nature, 626(7999), 466. https://doi.org/10.1038/d41586-024-00267-6
[6]. Willame, C., Dodd, C., van der Aa, L., Picelli, G., Emborg, H. D., Kahlert, J., Gini, R., Huerta, C., Martín-Merino, E., McGee, C., de Lusignan, S., Roberto, G., Villa, M., Weibel, D., Titievsky, L., & Sturkenboom, M. C. J. M. (2021). Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. Drug safety, 44(3), 383–395. https://doi.org/10.1007/s40264-020-01031-1
[7]. Zou, Y. F., Feng, C. C., Zhu, J. M., Tao, J. H., Chen, G. M., Ye, Q. L., Cen, H., Leng, R. X., Pan, F. M., Pan, H. F., Li, R., Fan, Y. G., Wang, B., Li, X. P., Zhang, F. Y., & Ye, D. Q. (2014). Prevalence of systemic lupus erythematosus and risk factors in rural areas of Anhui Province. Rheumatology international, 34(3), 347–356. https://doi.org/10.1007/s00296-013-2902-1
[8]. WUH, CHENY, ZHUH, (2019). Thepathogenicroleofdysregu‐ lated epigenetic modifications in autoimmune diseases. Front Immunol, 10:2305. DOI:10. 3389/fimmu. 2019. 02305.
[9]. Drougkas, K., Skarlis, C., & Mavragani, C. (2024). Type I Interferons in Systemic Autoimmune Rheumatic Diseases: Pathogenesis, Clinical Features and Treatment Options. Mediterranean journal of rheumatology, 35(Suppl 2), 365–380. https://doi.org/10.31138/mjr.270324.tis
[10]. Tullus, K., Webb, H., & Bagga, A. (2018). Management of steroid-resistant nephrotic syndrome in children and adolescents. The Lancet. Child & adolescent health, 2(12), 880–890. https://doi.org/10.1016/S2352-4642(18)30283-9
[11]. Vandewalle, J., Luypaert, A., De Bosscher, K., & Libert, C. (2018). Therapeutic Mechanisms of Glucocorticoids. Trends in endocrinology and metabolism: TEM, 29(1), 42–54. https://doi.org/10.1016/j.tem.2017.10.010
[12]. Fardet, L., & Fève, B. (2014). Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs, 74(15), 1731–1745. https://doi.org/10.1007/s40265-014-0282-9
[13]. van Staa, T. P., Leufkens, H. G., & Cooper, C. (2002). The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 13(10), 777–787. https://doi.org/10.1007/s001980200108
[14]. Bahtiyar, S., Gulmez Karaca, K., Henckens, M. J. A. G., & Roozendaal, B. (2020). Norepinephrine and glucocorticoid effects on the brain mechanisms underlying memory accuracy and generalization. Molecular and cellular neurosciences, 108, 103537. https://doi.org/10.1016/j.mcn.2020.103537
[15]. Baldwin, D., & Apel, J. (2013). Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes. Current diabetes reports, 13(1), 114–120. https://doi.org/10.1007/s11892-012-0339-7
[16]. Zdanowicz M. M. (2009). The pharmacology of immunosuppression. American journal of pharmaceutical education, 73(8), 144. https://doi.org/10.5688/aj7308144
[17]. ZW Dong, CW Chen, XC We.(2018). Research status and prospect of commonly used drugs for the treatment of osteoarthritis [J]. Chinese Journal of Geriatric Orthopedics and Rehabilitation Electronic Journal, 4(4): 252-256.
[18]. Padjen, I., Crnogaj, M. R., & Anić, B. (2020). Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms. Reumatologia, 58(6), 390–400. https://doi.org/10.5114/reum.2020.101400
[19]. Dervieux, T., Furst, D., Lein, D. O., Capps, R., Smith, K., Caldwell, J., & Kremer, J. (2005). Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Annals of the rheumatic diseases, 64(8), 1180–1185. https://doi.org/10.1136/ard.2004.033399
[20]. YH Su, G Wang, ZH Wen. (2021). Research progress in the pathogenesis and drug treatment of rheumatoid arthritis[J]. Northwest Journal of Pharmacy, 36(5):857-862.
[21]. Viret, C., Barlow, A. K., & Janeway, C. A., Jr (1999). On the intrathymic intercellular transfer of self-determinants. Immunology today, 20(1), 8–10. https://doi.org/10.1016/s0167-5699(98)01372-3
[22]. CG Yan, Q Xie. (2005). The formation and breaking of immune tolerance. Chinese Journal of Immunolog, (12):953-956.
[23]. Akadeum Life Sciences. (2024, September 4). Immunological tolerance: Types of tolerance in immunology. https://www.akadeum.com/blog/what-is-immune-tolerance/
[24]. Tremain, A. C., Wallace, R. P., Lorentz, K. M., Thornley, T. B., Antane, J. T., Raczy, M. R., Reda, J. W., Alpar, A. T., Slezak, A. J., Watkins, E. A., Maulloo, C. D., Budina, E., Solanki, A., Nguyen, M., Bischoff, D. J., Harrington, J. L., Mishra, R., Conley, G. P., Marlin, R., Dereuddre-Bosquet, N., … Hubbell, J. A. (2023). Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses. Nature biomedical engineering, 7(9), 1142–1155. https://doi.org/10.1038/s41551-023-01086-2
[25]. Binder, C., Cvetkovski, F., Sellberg, F., Berg, S., Paternina Visbal, H., Sachs, D. H., Berglund, E., & Berglund, D. (2020). CD2 Immunobiology. Frontiers in immunology, 11, 1090. https://doi.org/10.3389/fimmu.2020.01090
[26]. Grando Alves, G., Cunha, L., Henkes Machado, R., & Lins de Menezes, V. (2024). Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials. Diabetes, obesity & metabolism, 26(7), 2652–2661. https://doi.org/10.1111/dom.15581
[27]. Peterson R. A. (2012). Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicologic pathology, 40(2), 186–204. https://doi.org/10.1177/0192623311430693
[28]. Mashayekhi, K., Khazaie, K., Faubion, W. A., Jr, & Kim, G. B. (2024). Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment. Bioactive materials, 37, 269–298. https://doi.org/10.1016/j.bioactmat.2024.03.030
[29]. von Herrath, M., Sanda, S., & Herold, K. (2007). Type 1 diabetes as a relapsing-remitting disease? Nature reviews. Immunology, 7(12), 988–994. https://doi.org/10.1038/nri2192
[30]. Pozzilli, P., Pitocco, D., Visalli, N., Cavallo, M. G., Buzzetti, R., Crinò, A., Spera, S., Suraci, C., Multari, G., Cervoni, M., Manca Bitti, M. L., Matteoli, M. C., Marietti, G., Ferrazzoli, F., Cassone Faldetta, M. R., Giordano, C., Sbriglia, M., Sarugeri, E., & Ghirlanda, G. (2000). No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia, 43(8), 1000–1004. https://doi.org/10.1007/s001250051482
[31]. Blanas, E., Carbone, F. R., Allison, J., Miller, J. F., & Heath, W. R. (1996). Induction of autoimmune diabetes by oral administration of autoantigen. Science (New York, N.Y.), 274(5293), 1707–1709. https://doi.org/10.1126/science.274.5293.1707
[32]. Skyler, J. S., & Type 1 Diabetes TrialNet Study Group (2008). Update on worldwide efforts to prevent type 1 diabetes. Annals of the New York Academy of Sciences, 1150, 190–196. https://doi.org/10.1196/annals.1447.055
[33]. Rizava, C., Bekiari, E., Liakos, A., Sarigianni, M., Rika, M., Haidich, A. B., Galli-Tsinopoulou, A., & Tsapas, A. (2016). Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis. Endocrine, 54(3), 620–633. https://doi.org/10.1007/s12020-016-1033-3
[34]. Kaufman, D. L., Clare-Salzler, M., Tian, J., Forsthuber, T., Ting, G. S., Robinson, P., Atkinson, M. A., Sercarz, E. E., Tobin, A. J., & Lehmann, P. V. (1993). Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature, 366(6450), 69–72. https://doi.org/10.1038/366069a0
[35]. Orban, T., Farkas, K., Jalahej, H., Kis, J., Treszl, A., Falk, B., Reijonen, H., Wolfsdorf, J., Ricker, A., Matthews, J. B., Tchao, N., Sayre, P., & Bianchine, P. (2010). Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. Journal of autoimmunity, 34(4), 408–415. https://doi.org/10.1016/j.jaut.2009.10.005
[36]. Fousteri, G., Dave, A., Bot, A., Juntti, T., Omid, S., & von Herrath, M. (2010). Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia, 53(9), 1958–1970. https://doi.org/10.1007/s00125-010-1777-x
[37]. Jin, X., Dong, T., Wang, Q., Xie, Y., Fang, X., Wei, C., Liu, S., Zheng, X., Wang, P., Zhu, D., Cao, L., Dong, S., Fang, K., Zhong, C., Wang, J., Hu, F., & Li, Z. (2024). A citrullinated antigenic vaccine in treatment of autoimmune arthritis. Science bulletin, S2095-9273(24)00561-9. Advance online publication. https://doi.org/10.1016/j.scib.2024.02.042
[38]. Liu, X., Zhang, W., Zhao, M., Fu, L., Liu, L., Wu, J., Luo, S., Wang, L., Wang, Z., Lin, L., Liu, Y., Wang, S., Yang, Y., Luo, L., Jiang, J., Wang, X., Tan, Y., Li, T., Zhu, B., Zhao, Y., … Lu, Q. (2019). T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. Annals of the rheumatic diseases, 78(8), 1070–1078. https://doi.org/10.1136/annrheumdis-2019-215442
[39]. Xiao, J., Li, S., Wang, W., Li, Y., & Zhao, W. (2007). Protective effects of overexpression TCR Vbeta5.2-HSP70 and TCR Vbeta8.2-HSP70 against collagen-induced arthritis in rats. Cellular & molecular immunology, 4(6), 439–445.
[40]. Ge, P. L., Ma, L. P., Wang, W., Li, Y., & Zhao, W. M. (2009). Inhibition of collagen-induced arthritis by DNA vaccines encoding TCR Vbeta5.2 and TCR Vbeta8.2. Chinese medical journal, 122(9), 1039–1048.
[41]. KiriakidouM, ChingCL. (2020). Systemic lupus erythematosus. Ann Intern Med, 172(11): ITC81-ITC96.doi:10.7326/AITC202006020.
Cite this article
Xu,W. (2024). Progress in autoimmune disease and vaccine. Theoretical and Natural Science,71,133-141.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2024 Workshop: Computational Proteomics in Drug Discovery and Development from Medicinal Plants
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).